Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could represent a promising advancement for body treatment. Preliminary https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026